Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anti-interleukin-4 therapy.

John W Steinke1

  • 1Asthma and Allergic Diseases Center, Bierne Carter Center for Immunology, University of Virginia Health System, Lane Road, MR4 Building, Room 5031, Box 801355, Charlottesville, VA 22908-1355, USA. js3ch@virginia.edu

Immunology and Allergy Clinics of North America
|October 12, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of omalizumab across different dosing regimens in patients with moderate-to-severe allergic asthma.

Respiratory medicine·2024
Same author

Omalizumab improves sleep and health status for patients with chronic rhinosinusitis with nasal polyps: An analysis of randomized clinical trials.

International forum of allergy & rhinology·2024
Same author

Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2023
Same author

Improvement of Subjective Olfactory Dysfunction in Chronic Rhinosinusitis With Nasal Polyps After Endoscopic Sinus Surgery.

Frontiers in surgery·2022
Same author

Lower viral loads in subjects with rhinovirus-challenged allergy despite reduced innate immunity.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2022
Same author

Interleukin-5 receptor alpha (CD125) expression on human blood and lung neutrophils.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2021
Same journal

Anaphylaxis: State-of-the-Art.

Immunology and allergy clinics of North America·2026
Same journal

Upending Impending Doom.

Immunology and allergy clinics of North America·2026
Same journal

Mast Cell Activation Syndrome and Mimickers.

Immunology and allergy clinics of North America·2026
Same journal

Hereditary Alpha-Tryptasemia (HαT) as a Risk Modifier for Severe Anaphylaxis.

Immunology and allergy clinics of North America·2026
Same journal

Emerging Therapies for Anaphylaxis.

Immunology and allergy clinics of North America·2026
Same journal

Novel Epinephrine Delivery Devices.

Immunology and allergy clinics of North America·2026
See all related articles

Interleukin 4 (IL-4) drives inflammation in asthma by promoting allergic responses and mucus production. Anti-IL-4 therapies are being developed to target these pro-inflammatory pathways for asthma treatment.

Area of Science:

  • Immunology
  • Pulmonology
  • Pharmacology

Background:

  • Interleukin 4 (IL-4) plays a critical role in mediating pro-inflammatory functions relevant to asthma pathogenesis.
  • These functions include T helper cell type 2 differentiation, IgE production, and eosinophil recruitment.
  • Genetic evidence, such as IL-4 gene polymorphisms, supports its role in asthma.

Purpose of the Study:

  • To examine the role of Interleukin 4 (IL-4) in asthma.
  • To review current and past clinical development of IL-4 antagonists.
  • To discuss early trial results and future prospects of anti-IL-4 therapy.

Main Methods:

  • Review of scientific literature on IL-4 and asthma.
  • Analysis of clinical trial data for IL-4 antagonists.

Related Experiment Videos

  • Discussion of the biological mechanisms of IL-4 action in asthma.

    • Main Results:

    • IL-4 mediates key inflammatory processes in asthma, including IgE induction and eosinophil infiltration.
    • Polymorphisms in the IL-4 gene are associated with asthma.
    • Several IL-4 antagonism strategies have entered clinical development.

    Conclusions:

    • IL-4 is a significant mediator in asthma.
    • Targeting IL-4 with antagonists represents a promising therapeutic strategy.
    • Further clinical evaluation is needed to establish the efficacy and safety of anti-IL-4 therapies.